| London Stock Exchange: BTG
BTG Plc develops, manufactures and supplies drugs used in the treatment of neurological disorders. The company in-licenses, develops and commercializes pharmaceuticals and has a broad pipeline of research and development programmes targeting neurological and other disorders, including varicose veins. Its products include a treatment for snakebites, antidotes to treat toxicity associated with medicines used for heart conditions and cancer and interventional oncology products that are used to treat patients with liver or prostate tumours. The company operates through three reportable segments, being Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology. The Interventional Medicine segment represents the portfolio of beads and brachytherapy products acquired with Biocompatibles. The Licensing & Biotechnology segment includes revenues from BTG's licensed portfolio of intellectual property as well as income from the acquired Biocompatibles business. The company was founded in 1981 and is headquartered in London, the United Kingdom.